XLRN

Acceleron Pharma Inc. Press Releases

$40.48
*  
0.75
1.89%
Get XLRN Alerts
*Delayed - data as of Dec. 18, 2014  -  Find a broker to begin trading XLRN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    XLRN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
12/15/2014 8:00:00 AM - Business Wire


Acceleron Pharma Added to NASDAQ Biotechnology Index
12/15/2014 8:00:00 AM - Business Wire
▼-3.09 % Price Change since this news event. The Volume Ratio is 0.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors
12/12/2014 7:30:00 AM - Business Wire
▼-2.41 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Luspatercept Data on Myelodysplastic Syndromes Selected for “Best of ASH” by the American Society of Hematology
12/10/2014 7:30:00 AM - Business Wire
▼-6.75 % Price Change since this news event. The Volume Ratio is 0.61.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition
12/8/2014 2:00:00 PM - Business Wire


New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition
12/7/2014 12:00:00 PM - Business Wire


UMeWorld Provides Shareholder Update
11/24/2014 7:30:00 AM - Business Wire


Acceleron Pharma to Present at Upcoming Investor Conferences in December
11/24/2014 7:30:00 AM - Business Wire


Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014
11/13/2014 9:30:00 AM - Business Wire
▲20.12 % Price Change since this news event. The Volume Ratio is 4.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome
11/13/2014 8:30:00 AM - PR Newswire
▲19.80 % Price Change since this news event. The Volume Ratio is 4.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results
11/7/2014 7:30:00 AM - Business Wire
▲18.57 % Price Change since this news event. The Volume Ratio is 1.44.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Announces New Clinical Data Presentations at the 2014 American Society of Hematology Annual Meeting
11/6/2014 9:32:00 AM - Business Wire
▲21.13 % Price Change since this news event. The Volume Ratio is 0.47.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Pharma to Host Third Quarter 2014 Financial Results Conference Call and Webcast on November 7, 2014
10/30/2014 7:30:00 AM - Business Wire
▲16.52 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Pharma to Present at Upcoming Investor Conferences in November
10/29/2014 7:30:00 AM - Business Wire
▲12.98 % Price Change since this news event. The Volume Ratio is 0.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014
10/23/2014 10:52:00 AM - Business Wire
▲35.16 % Price Change since this news event. The Volume Ratio is 2.47.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder
10/22/2014 7:30:00 AM - Business Wire
▲38.96 % Price Change since this news event. The Volume Ratio is 0.4.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083
10/14/2014 7:30:00 AM - Business Wire
▲36.90 % Price Change since this news event. The Volume Ratio is 2.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Acceleron to Host Educational Webcast on Beta-thalassemia
10/1/2014 7:30:00 AM - Business Wire


Acceleron to Webcast Presentation at Leerink Partners Rare Disease Roundtable
9/29/2014 7:30:00 AM - Business Wire


Acceleron Provides Update on Externally Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer
9/23/2014 8:30:00 AM - Business Wire